Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology
Clinical Trials: Head and Neck Cancer
A listing of clinical trials currently looking for volunteers to enroll in Head and Neck Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham (UAB)
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
Birmingham : University of Alabama at Birmingham
Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
Birmingham : University of Alabama at Birmingham
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
Arizona
California
Duarte : City of Hope Updated New
PHII-113, NCI #8474: A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects with Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) (IND 71976)
Duarte : City of Hope Updated
RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Escondido : Southwest Cancer Care
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Greenbrae : Marin Cancer Care, Inc.
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Greenbrae : Marin Cancer Care
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Los Angeles : Kenmar Research Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Oxnard : Ventura County Hematology Oncology Specialists
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Alhambra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Bakersfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Encinitas : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Fullerton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Northridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Redondo Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Santa Maria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Stanford : Stanford University School of Medicine
Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer
Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Colorado
Connecticut
New Haven : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Florida
Jacksonville : Integrated Community Oncology Network
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Miami : Advanced Medical Specialties
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
New Port Richey : Pasco Pinellas Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Tampa : H. Lee Moffitt Cancer Center & Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Weston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Georgia
Illinois
Elgin : Sherman Health
ECOG E1305 - A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
View More »
Chicago : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Chicago : The University of Chicago Medical Center
Randomized Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Indiana
Kansas
Maryland
Bethesda : Center for Cancer and Blood Disorders
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Baltimore : Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in NNSCC
Salisbury : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Massachusetts
Michigan
Mississippi
Missouri
Nebraska
Nevada
New Hampshire
New Jersey
New York
Bronx : Montefiore Medical Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Bronx : Bronx Lebanon Hospital
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Bronx : Bronx Lebannon - BRANY
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Buffalo : Roswell Park Cancer Institute
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Latham : New York Oncology, Hematology
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Manhasset : Biomedical Research Alliance of New York
Head and Neck Cancer - Adults
View More »
Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Bronx : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Commack : Memorial Sloan-Kettering Cancer Center at Commack
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
New York : Memorial Sloan Kettering Cancer Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
New York : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
New York : Memorial Sloan Kettering Cancer Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Rockville Centre : Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
North Carolina
Durham : Duke University
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Chapel Hill : University of North Carolina at Chapel Hill
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Durham : Duke University Medical Center
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Durham : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Goldsboro : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Winston-Salem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Ohio
Oregon
Pennsylvania
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Pittsburgh : University of Pittsburgh Medical Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Philadelphia : Fox Chase Cancer Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Philadelphia : Thomas Jefferson University
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
South Carolina
Tennessee
Nashville : Sarah Cannon Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Nashville : Vanderbilt University
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Texas
Austin : Texas Oncology – South Austin
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Dallas : Texas Oncology - Baylor - Charles A. Sammons Cancer Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Dallas : UT Southwestern Medical Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Dallas : Mary Crowley Cancer Research Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Head And Neck
View More »
Abilene : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Amarillo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Arlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Ft. Worth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Houston : UT MD Anderson Cancer Center
Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Houston : Baylor College of Medicine
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
Houston : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Houston : UT MD Anderson Cancer Center
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
Odessa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
San Marcos : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Tyler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Virginia
Washington
West Virginia
Wisconsin
Madison : University Of Wisconsin
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Canada
Edmonton : Cross Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Laval : Cité de la Santé de Laval
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Montreal : Maisonneuve-Rosemont Hospital Research Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Toronto, Ontario : Princess Margaret Hospital
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Calgary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Edmonton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
London : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Montreal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Ottawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Québec : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Québec : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Toronto : Princess Margaret Hospital
A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Toronto : Local Institution
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Vancouver : Local Institution
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Finland
Helsinki : Department of Oncology, Helsinki University Central Hospital
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
France
Clermont-Ferrand : Hotel Dieu
INEC Study: Immuno-modulating Enteral Nutrition in Cancer
Limoges Cedex : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Montpellier Cedex 5 : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Toulouse :
A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma
Villejuif :
A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma
View More »
Villejuif cedex : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Germany
Germany : University of Heidelberg Medical Center
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
Italy
Bologna : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Firenze (FI) : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Milano : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Padova : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Roma : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Korea, Republic of
Jung-gu Daejeon : Chungnam National University Hospital
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Mexico
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Merida : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Mitras Norte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Netherlands
Amsterdam : Netherlands Cancer Institute
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
Nijmegen : University Medical Center Nijmegen st Radboud
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
Poland
Warszawa : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
United Kingdom
Papworth Everard : Papworth Hospital NHS Trust
Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib
United States
